IrelandIreland

Shire expands haematology business with virtual company

16.03.2012

Dublin – Irish drugmaker Shire plc has agreed to pay US-$100m in upfront for Ferrokin Biosciences Inc., a San Francisco-based specialist for iron chelation therapies. US-$225m could be added if certain milestones are achieved. FerroKin is a virtual company founded by Hugh Young Rienhoff in 2007. It is working on a once-daily oral capsule to treat chronic blood transfusion patients suffering from iron overload, which increases the risk of heart, liver or other organ failures. Lead candidate FBS-0701 is in Phase II testing. "An important factor for FerroKin BioSciences in agreeing to this transaction was Shire's drive, capability and vision to bring new products to the haematology market that promise to raise the standard of care for patients," Rienhoff said in a press release. "In Shire's hands, FBS-0701 has greater potential to fulfil that promise." FerroKin was financed by Burrill & Co., Clarus Ventures, HealthCap Ventures and MP Venture. The acquisition is a strategic fit for Shire which plans to build up its haematology business unit. Shire already sells Xagrid to treat the overproduction of blood platelets.

Clinical Trial, Austria

21.07.2006

Intercell AG (Vienna, Austria) announced that an analysis of the pivotal immunogenicity phase III clinical data of its investigational Japanese Encephalitis virus (JEV) vaccine showed positive results and met its primary...

Clinical Trial, Switzerland

21.07.2006

ZymoGenetics, Inc. (Seattle, USA) and Serono S.A. (Geneva, Switzerland) announced favorable results from a Phase Ib clinical trial with TACI-Ig in 73 patients with rheumatoid arthritis (RA) at the end of June. The soluble fusion...

Editorial, Miscellaneous, Switzerland

12.05.2006

Now in it's fifth year, European Biotechnology News is more successful than ever as a Europe-wide specialized biotech magazine. Not only in Brussels, but in the individual countries of the European Union, and in Switzerland,...

Miscellaneous

12.05.2006

The first biosimilar will soon be arriving on pharmacy shelves in Europe. In mid-April, the European Commission granted a marketing authorization to Omnitrope (somatropin), a recombinant growth hormone produced by Sandoz....

Miscellaneous

12.05.2006

The global biotech industry again achieved a double-digit growth in 2005. Although Europe was not able to compete with the figures from the US sector, as in 2004, it has recovered from a lengthy restructuring period.

Miscellaneous

12.05.2006

Chicago - Unlike Europe, the USA can consider themselves lucky - there is only one essential annual biotechnology meeting, and with 19,479 attendees from 62 countries, the 14th Annual International Convention of the US-American...

Politics / Law

12.05.2006

In the USA it takes four days to establish a new company. In Europe, on average, it takes 45 days. In order to finally improve the starting conditions for technology-oriented companies, European parliamentarian and organization...

BioFunding

12.05.2006

The 25 European heads of governments have frozen European Commission president Manuael Barroso's plans to set up a European think tank in the mould of the US-based Massachusetts Institute of Technology (MIT). At the end of March,...

Politics / Law

12.05.2006

Parma/Basel - The Swiss agribiotech and plant protection company Syngenta AG has filed an application for a new genetically engineered maize line, intended to facilitate ethanol fuel production, to the European Food Safety...

Politics / Law

12.05.2006

Industry participation in the priority area 'health research' of the FP6 framework programme from the European Union has been boosted by a specific call for small-and medium-sized enterprises (SMEs) to apply for funding. SME...

Displaying results 1021 to 1030 out of 1983

< Previous 1021-1030 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/102/article/shire-expands-haematology-business-with-virtual-company.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.69 EUR14.47%
  • BAYER112.70 EUR6.17%
  • CO.DON3.32 EUR5.40%

FLOP

  • SYNGENTA310.90 CHF-1.96%
  • SANTHERA88.05 CHF-1.23%
  • ADDEX3.10 CHF-0.96%

TOP

  • CO.DON3.32 EUR32.8%
  • PAION3.05 EUR27.1%
  • EPIGENOMICS3.83 EUR22.8%

FLOP

  • ADDEX3.10 CHF-22.5%
  • EVOTEC3.08 EUR-16.1%
  • MEDIGENE3.93 EUR-14.6%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR277.3%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • THERAMETRICS0.09 CHF-40.0%
  • BIOFRONTERA2.20 EUR-39.7%

No liability assumed, Date: 18.09.2014


Current issue

All issues

Product of the week

Products